0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R beta

IL-2 R beta

IL-2 R beta Molecule Information

Name:Interleukin-2 receptor alpha chain
Target Synonym:TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,IL2R,Insulin-Dependent Diabet
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

IL-2 R beta Protein Product ListCompare or Buy

IL-2 R beta Part of Bioactivity data

CD2-H5221-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2 R beta, His Tag (SPR verified) (Cat. No. CD2-H5221) inhibits the IL-15-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.38-0.45 µg/mL (Routinely tested).

ILB-H5253-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.473 μM as determined in a SPR assay (Biacore T200) (QC tested).

CD2-H5221-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R beta, His Tag (SPR verified) (Cat. No. CD2-H5221) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.525 μM as determined in a SPR assay (Biacore T200) (QC tested).

IL-2 R beta Molecule Synonym Name

IL2RB,RP5-1170K4.6,CD122,P70-75

IL-2 R beta Molecule Background

Interleukin-2 receptor (IL-2R) is a heterotrimeric protein expressed on the surface of certain immune cells, such as lymphocytes, that binds and responds to a cytokine called IL-2. The IL-2R is made up of 3 subunits - α (CD25), β (CD122) and γ (CD132) - non-covalently associating. The α and β chains are involved in binding IL-2, while signal transduction following cytokine interaction is carried out by the γ-chain, along with the β subunit. CD122 is also known as IL2R beta, is a member of the type I cytokine receptor family. CD122 is the receptor for interleukin-2 and is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.

IL-2 R beta References

IL-2 R beta Related Molecule

IL-2 R beta Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous s:9:"Eisai Inc"; 1999-02-05 Lymphoma, T-Cell, Peripheral; Leukemia; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation s:18:"Novartis Pharma Ag"; 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Recombinant humanized anti-CD25 monoclonal antibody (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation s:4:"null"; 2011-01-12 Rejection of renal transplantation Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis s:10:"Biogen Inc"; 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Colitis, Ulcerative; Asthma Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms s:67:"Liaoning Satellite Biological Products Research Institute (Limited)"; 2002-02-04 Neoplasms Details
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous s:9:"Eisai Inc"; 1999-02-05 Lymphoma, T-Cell, Peripheral; Leukemia; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation s:18:"Novartis Pharma Ag"; 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Recombinant humanized anti-CD25 monoclonal antibody (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation s:4:"null"; 2011-01-12 Rejection of renal transplantation Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis s:10:"Biogen Inc"; 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Colitis, Ulcerative; Asthma Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms s:67:"Liaoning Satellite Biological Products Research Institute (Limited)"; 2002-02-04 Neoplasms Details

IL-2 R beta Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Lymphoma, Mantle-Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Fallopian Tube Neoplasms; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Peripheral; Lymphoma, Follicular; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Solid tumours Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Lymphoma, Mantle-Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Fallopian Tube Neoplasms; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Myeloid, Acute; Burkitt Lymphoma; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, T-Cell, Peripheral; Lymphoma, Follicular; Urinary Bladder Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Solid tumours Details

This web search service is supported by Google Inc.

totop